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Abstract 
Background: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes 
care with a self-management intervention (SMI), with and without personalised risk information (including genetics), 
on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping 
assay, and the genetic characteristics of the recruits.
Methods: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score. Genetic CHD risk was 
determined by genotyping 19 single nucleotide polymorphisms (SNPs) using Randox’s Cardiac Risk Prediction Array 
and calculating a gene score (GS). Accuracy of the array was assessed by genotyping a subset of pre-genotyped 
samples (n = 185).
Results: Overall, 10-year CHD risk ranged from 2–72 % but did not differ between the randomisation groups 
(p = 0.13). The array results were 99.8 % concordant with the pre-determined genotypes. The GS did not differ 
between the Caucasian participants in the CoRDia SMI plus risk group (n = 66) (p = 0.80) and a sample of UK healthy 
men (n = 1360). The GS was also associated with LDL-cholesterol (p = 0.05) and family history (p = 0.03) in a sample 
of UK healthy men (n = 1360).
Conclusions: CHD risk is high in this group of T2D subjects. The risk array is an accurate genotyping assay, and is suit-
able for estimating an individual’s genetic CHD risk.
Trial registration This study has been registered at ClinicalTrials.gov; registration identifier NCT01891786
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Background
There has long been evidence from observational studies 
that those with type 2 diabetes (T2D) have an increased 
risk of coronary heart disease (CHD) [1] and recent 
genetic studies support a causal role for diabetes in CHD 
[2, 3]. Furthermore, there is evidence from randomised 
controlled trials that better glycaemic control results in 
better cardiovascular outcomes as well as reducing the 
risk of diabetic complications [4, 5].
Given the importance of diabetes management for 
cardiovascular health and evidence that patients often 
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have difficulty following recommended behaviour (e.g. 
maintaining a balanced diet and regular exercise), self-
management interventions (SMI) have been developed 
[6]. These structured group educational sessions led 
by trained facilitators allow patients to identify the dif-
ficulties they face in managing their diabetes with their 
peers, and use theory- and evidence-based techniques 
to enable patients to develop the skills to manage their 
health-related behaviours. The Coronary heart disease 
Risk in type 2 Diabetes (CoRDia) study was designed to 
investigate whether attendance at an SMI with and with-
out receiving personalised CHD risk information (includ-
ing conventional and genetic risk), resulted in improved 
glycaemic control and reduced CHD risk compared with 
usual care [7]. Ten-year risk of CHD was determined 
using the UKPDS score [8].
Gene scores can be used to provide an estimate of 
genetic risk for a particular phenotype. A 19 single nucle-
otide polymorphism (SNP) CHD gene score comprised 
of variants in risk loci identified by both candidate studies 
and genome-wide association studies (GWAS) has been 
found to be associated with CHD in those of Caucasian 
[9] and Afro-Caribbean ethnicity [10], although the rela-
tionship with CHD in those of South Asian ethnicity is 
unclear [9]. Furthermore, the gene score showed poten-
tial clinical utility in the UK population as in healthy UK 
subjects, when considering those who went up a risk cat-
egory with the addition of the gene score to the Framing-
ham risk score, a statistically significantly number were 
reclassified correctly. The gene score has not previously 
been tested in a group with type 2 diabetes.
Having collected the baseline clinical data, our first 
aim was to compare the conventional risk factor (CRF) 
data across the three CoRDia groups, and thus determine 
whether randomisation was effective. Our second aim 
was to examine the accuracy of genotyping performed 
using the Cardiac Risk Prediction array (Randox Labo-
ratories Ltd, Crumlin, Co Antrim, UK) to examine the 
accuracy of the SNP score genotyping protocol. Finally, 
we sought to compare the genetic profile of the recruits 
with a sample of healthy UK men to assess whether the 
results observed in the CoRDia study are applicable to 
the general population and to assess whether the gene 
score was associated with any risk factors for CHD.
Methods
CoRDia
The protocol for the CoRDia study has been described in 
detail elsewhere [7]. Briefly, 211 patients with poorly con-
trolled T2D [defined by a glycated haemoglobin (hba1c) 
level ≥ 6.45 %] were recruited from primary care in the 
East of England. Each participant was randomised into 
one of three arms; (i) usual care, (ii) SMI only or (iii) 
SMI plus personalised CHD risk (SMI plus risk results—
SMI + RR). Sample size was based on a power calcula-
tion for the number of participants required to detect a 
6.25  % difference in glycated haemoglobin levels (i.e. a 
clinically achievable reduction) between any of the study 
groups after follow-up of 12 months. This allows for both 
increased motivation in our intervention groups and thus 
a decrease in these group(s) compared to the control 
group (as we would hypothesise) but also that partici-
pants may be de-motived by knowledge of their personal 
CHD risk resulting in an increase compared to the con-
trol group. Personalised CHD risk was determined using 
the UKPDS risk score [8]. The UKPDS score includes age 
of T2D onset, sex, Afro-Caribbean ethnicity, total choles-
terol, high density lipoprotein (HDL) cholesterol, systolic 
blood pressure, duration of diabetes, smoking and gly-
cated haemoglobin, and calculates the risk of developing 
CHD in those with T2D in the next 10 years. A combined 
CHD risk score was determined for individuals in  the 
SMI + RR group where the UKPDS score was combined 
with the 19 SNP CHD gene score [9]. The participants 
aged between 25 and 74  years and were of Caucasian, 
Afro-Caribbean, Asian Indian, mixed Caucasian/Afro-
Caribbean or mixed Caucasian/Asian Indian ethnic-
ity. When calculating the UKPDS score those of mixed 
Caucasian/Afro-Caribbean ethnicity were coded as 
non-Afro-Caribbean (ethnicity is a binary variable based 
on Afro-Caribbean ethnicity in the UKPDS score) as sug-
gested by the developers of the UKPDS risk score. All 
participants were free of cardiovascular disease at base-
line. Recruits into the SMI + RR arm consented to pro-
vide a saliva sample for analysis using the Oragene DNA 
Self-collection Kit (DNA Genotek Inc., Ontario, Canada). 
Collected samples were marked with a barcode and 
posted to the genetics laboratory at UCL. Samples were 
received within approximately one week. Ethical approval 
for this study has been granted by the East of England 
Research Ethics Committee (ref 12/EE/0437) and the 
study complied with the ethical principles underlying the 
Declaration of Helsinki. This study has been registered at 
ClinicalTrials.gov; registration identifier NCT01891786.
Healthy subject comparison group
Healthy UK men were selected from the second North-
wick Park Heart Study (NPHSII) [11], which is a prospec-
tive study of middle-aged Caucasian men recruited from 
general practices in the UK. Participants were free of 
cardiovascular disease at baseline. There was a median of 
13.5 years follow-up. CHD was defined as acute myocar-
dial infarction (MI), silent MI or having undergone coro-
nary surgery. Family history of early CHD was collected 
as reported previously [12]. Complete genotype data was 
available for 1360 men. Ethical approval was given from 
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the national research ethics service (NRES) Committee 
London-Central.
Genotyping
Genotyping of NPHSII samples was performed on DNA 
extracted from blood and carried out using Taqman 
(Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA) and KASPar (LGC, Teddington, UK) genotyping 
assays as well as restriction fragment length polymor-
phism (RFLP) analysis. For the CoRDia SMI + RR arm, 
saliva was collected using the Oragene-DNA OG-250 
and DNA manually purified using DNA Genotek’s 
PrepIt-L2P DNA extraction kit (DNA Genotek Inc., 
Ontario, Canada). Individuals in the CoRDia SMI + RR 
arm and selected NPHSII samples (n = 185) were geno-
typed using the Cardiac Risk Prediction Array (Randox 
Laboratories Ltd, Crumlin, Co Antrim, UK) according 
to the manufacturer’s instructions. The Cardiac Risk 
Prediction Array is a multiplex SNP genotyping system 
which uses Randox’s Biochip Array Technology [13] to 
genotype 19 CHD risk SNPs. The protocol involves using 
multiplex PCR to amplify target DNA in an allele-spe-
cific manner. Amplicons are detected by hybridisation 
to spatially tethered probes on the biochip array surface. 
Each position on the biochip array corresponds to a spe-
cific allele and genotypes are determined using the Evi-
dence Investigator Analyser. In some instances (e.g. for 
rare genotypes) Sanger sequencing was used to confirm 
the result.
Statistical analysis
Statistical analysis was carried out using R version 3.1.2. 
The gene score was calculated as detailed previously [9]. 
Briefly, the number of risk alleles for a particular SNP 
was multiplied by the effect size pertaining to the asso-
ciation between that SNP and CHD (apart for rs1799983 
which was treated in a recessive manner). The UKPDS 
score was calculated as described in [8]. For the CoRDia 
SMI + RR group the gene score was calculated and com-
bined with the UKPDS score using a proprietary algo-
rithm (Storegene, http://www.storegene.com/) to give a 
combined risk score. Briefly, to combine the gene score 
with the UKPDS score, the relative odds ratio deter-
mined by the gene score was converted to relative risk 
(incidence of CHD in this group was set at 0.3: calcu-
lated using data published by the British Heart Founda-
tion [14]) and included as a term in the calculation of “q” 
(used to calculate the UKPDS score). Combined ten-year 
CHD risk could then be calculated by exponentiating the 
product of “q” and (1-duration of T2D^10)/1-duration 
of T2D) and subtracting it from one. Clinical and demo-
graphic variables were compared across the three ran-
domisation groups using ANOVA for numerical data 
and Chi squared tests for categorical data. A difference of 
p ≤ 0.05 was taken as statistically significant.
Results
The baseline characteristics of the participants in the 
CoRDia study are shown in Table  1. Of the T2D-CHD 
risk factors, only sex and HDL-cholesterol were found 
to differ between the three randomisation groups 
(p = 0.05). The 10-year risk of CHD in the whole of the 
CoRDia study (n = 211) ranged from 2–72 % as shown in 
Fig. 1a and did not differ significantly between the study 
groups (p = 0.13). Median UKPDS CHD risk in the CoR-
Dia subjects (n =  211) was 14.89 % (interquartile range 
8.58–23.53  %). For reference, the median Framingham 
CHD risk was 10.56 % (interquartile range 7.30–15.56 %) 
in the NPHSII cohort (n  =  2948), although the CHD 
risks cannot be directly compared as they were calculated 
using different scores. 
The saliva collection method and DNA extraction pro-
cedure was successful for all samples and the yield of 
DNA ranged from 5–100  µg. To validate the method-
ology, genotyping of a sub-sample (n  =  185) from the 
NPHSII cohort of healthy UK subjects for the 19 SNPs 
was carried out using the Cardiac Risk Prediction Array. 
This was compared against methods previously used (rel-
evant data was not available for all SNPs from the pre-
determined samples), and results are detailed in Table 2. 
There was 100 % concordance between the array results 
and pre-determined genotypes for fourteen of the nine-
teen SNPs. For four of the remaining five SNPs (located 
in APOE, APOB, CETP and LPL) there was only one dis-
cordant result and for the fifth (located close to MIA3) 
there were two discordant results. Overall for the 19 gen-
otypes the concordance rate was 3152/3158 = 99.8 %.
The genetic risk profile of the CoRDia recruits was 
compared to that of a cohort of healthy UK men, NPH-
SII. As the subjects in this group were all of Caucasian 
ethnicity, the analysis was performed after removal of the 
non-Caucasian participants from the CoRDia SMI + RR 
group. The distribution of risk alleles in the UK healthy 
men (n  =  1360) and the Caucasian participants in the 
CoRDia SMI + RR group (n = 66 as there were four non-
Caucasian participants in this group) is shown in Fig. 2. 
The range of risk alleles carried in the healthy men was 
9-22 with a median number of 16. The range of risk alleles 
carried in the CoRDia SMI + RR group was 10–20, with 
a median number of 14. There was no significant differ-
ence in distribution of risk alleles between the two groups 
(as determined by Chi squared test, p = 0.53). When the 
gene score was calculated, weighting the carriage of the 
SNP for its reported CHD risk effect, there was no signif-
icant difference in mean gene score between the Cauca-
sian participants of the CoRDia SMI + RR group and the 
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group of healthy UK men (3.14 vs 3.17 p = 0.80, Fig. 3). 
The gene score was then combined with the UKPDS risk 
to give an overall ten-year risk of CHD. This ranged from 
3–66 % (Fig. 1b).
To study the relationship between classical CHD risk 
factors and the gene score we divided the gene score 
into tertiles and performed regression analysis with the 
NPHSII data. The gene score was associated only with 
low density lipoprotein (LDL) cholesterol, with those in 
the top tertile of the score having 0.14 mmol/l higher lev-
els than those in the bottom tertile (p = 0.05) and with 
family history of early CHD, with prevalence in the top 
tertile being 7 % higher than the bottom tertile (p = 0.03) 
(Table 4). For comparison, a similar analysis of the rela-
tionship between the gene score and T2D-CHD CRFs 
included in the UKPDS score is presented in Table 3 in 
the CoRDia SMI  +  RR group. In this small sample the 
gene score was not significantly associated with any of 
the variables assessed.
Discussion
We have presented the baseline characteristics and 
genetic profile of the CoRDia study recruits, all of whom 
have T2D. The use of the T2D specific CHD risk calcu-
lator UKPDS, aims to take of account of the impact of 
diabetes management as well as its duration on risk of 
CHD, information which is not captured using risk mod-
els from the general population. The range UKPDS ten-
year CHD-risk score observed in the CoRDia recruits of 
2–72 % is similar to that observed in the general popu-
lation with T2D [15] and to the Caucasian participants 
of the University College London Diabetes and Cardio-
vascular Disease Study (UDACS) [16] where the range of 
UKPDS 10-year CHD-risk scores in the Caucasian par-
ticipants without CHD was 1–87  %. Furthermore, the 
UKPDS risk scores did not differ significantly between 
the three study groups demonstrating successful ran-
domisation of the participants.
The use of saliva as a sample matrix proved effective, 
providing a high yield of good quality DNA, demon-
strated by its use with both the Cardiac Risk Prediction 
Array and as template DNA for Sanger sequencing. A 
further benefit was that samples, once collected, are 
Table 1 Baseline characteristics of the CoRDia participants by randomisation group
The mean plus standard deviation is shown, where appropriate. Numeric variables were compared using ANOVA and categorical variables were compared using Chi 
squared tests
HDL high density lipoprotein, T2D type 2 diabetes, SMI self-management intervention, RR risk report
a Variable was log transformed. Geometric mean and approximate standard deviation are shown (except UKPDS risk score where the inter-quartile range is shown)
b Variable was square root transformed, means were transformed back and the range is shown
Trait CoRDia control group 
(n = 67)
CoRDia SMI only group 
(n = 74)
CoRDia SMI + RR group 
(n = 70)
p value
Age (years) 61.40 (10.08) 61.28 (9.11) 62.36 (7.42) 0.53
Sex (% female) 48 % (n = 33) 46 % (n = 40) 34 % (n = 24) 0.05
Ethnicity (% European) 92 % (n = 60) 92 % (n = 68) 94 % (n = 66) 0.65
Total cholesterol (mmol/l)a 4.18 (0.97) 4.36 (0.89) 4.29 (1.03) 0.55
HDL-cholesterol (mmol/l)a 1.27 (0.29) 1.23 (0.37) 1.16 (0.29) 0.05
Systolic blood pressure (mmHg) 133.93 (12.56) 134.36 (14.41) 133.44 (12.97) 0.97
Duration of T2D (years)b 5.60 (0–23) 5.60 (0–39) 6.33 (0–23) 0.38
Age of T2D onset (years) 55.00 (10.87) 54.99 (10.17) 54.90 (8.36) 0.95
Glycated haemoglobin (%)a 7.73 (1.29) 7.60 (1.03) 7.58 (0.99) 0.41
Smoking (n) 7 % (n = 5) 5 % (n = 4) 16 % (n = 11) 0.09
UKPDS risk score (%)a 13.40 (8.28–22.90) 14.36 (8.02–22.02) 17.25 (9.40–26.53) 0.13
Fig. 1 Distribution of a UKPDS risk score in CoRDia participants 
(n = 210*) and b Combined risk score (UKPDS plus genetic risk) in 
CoRDia SMI plus risk results group (n = 70)
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stable, easily stored and could be posted to the genet-
ics lab. Furthermore, the Cardiac Risk Prediction Array 
showed very high concordance with the other geno-
typing methods used (99.8  %). A number of the SNPs 
included in the gene score have low minor allele frequen-
cies (MAF), consequently few samples with these alleles 
were available for testing and thus confidence intervals 
for the concordance values given are large. Three of the 
19 SNPs, rs3798820 in LPA, rs11591147 in PCSK9 and 
rs1801177 in LPL have MAFs below 0.05 in NPHSII. As 
such, we were only able to test a few heterozygous sam-
ples and no rare homozygous samples for these SNPs. 
Table 2 Performance of the randox cardiac risk prediction array





RAF in NPHSII Genotype distribution % Concordance (n)
Common homozy-
gotes (n)
Heterozygotes (n) Rare homozygotes 
(n)
rs11591147 PCSK9 1 0.99 139 5 0 100 (144)
rs17465637 MIA3 1 0.71 84 68 6 98.7 (158)
rs646776 SORT1 1 0.78 95 69 8 100 (172)
rs1042031 APOB 2 0.18 105 62 6 99.4 (173)
rs9818870 MRAS 3 0.16 116 44 5 100 (165)
rs3798220 LPA 6 0.02 166 7 0 100 (173)
rs10455872 LPA 6 0.07 135 20 1 100 (156)
rs1799983 NOS3 7 0.33 68 79 24 100 (171)
rs328 LPL 8 0.90 131 34 2 99.4 (167)
rs1801177 LPL 8 0.01 162 5 0 100 (167)
rs7025486 DAB2IP 9 0.26 94 69 10 100 (173)
rs10757274 9p21 9 0.48 57 84 33 100 (174)
rs1746048 CXCL12 10 0.86 129 41 4 100 (174)
rs662799 APOA5 11 0.06 133 13 2 100 (148)
rs17228212 SMAD3 15 0.31 83 72 18 100 (173)
rs708272 CETP 16 0.56 50 71 26 99.4 (158)
rs4341 ACE 17 0.52 47 81 40 100 (168)
rs7412 APOE 19 0.91 131 36 5 99.4 (172)
rs429358 APOE 19 0.17 139 32 1 100 (172)
Table 3 Association of gene score with T2D-CHD risk factors in the CoRDia SMI + RR study participants
Gene score was divided into tertiles. Linear regression was performed for the numeric variables and logistic regression was performed for the categorical variables. 
Mean value and standard deviation for each tertile is shown except for log transformed variables were the geometric mean and approximate standard deviation are 
shown and square root transformed variables where means were transformed back and the range is shown
HDL high density lipoprotein, T2D type 2 diabetes, CHD coronary heart disease
a Variable was log transformed
b Variable was square root transformed
Trait Tertile 1 (n = 24) Tertile 2 (n = 23) Tertile 3 (n = 23) p value
Age (years) 62.88 (6.96) 61.61 (8.15) 62.57 (7.38) 0.88
Sex (% female) 38 % (n = 9) 39 % n = 9 26 % n = 6 0.42
Ethnicity (% non Afro-Caribbean) 100 % 91 % (n = 21) 100 % 0.98
Total cholesterol (mmol/l) 4.26 (1.27) 4.58 (1.21) 4.42 (0.77) 0.63
HDL-cholesterol (mmol/l)a 1.21 (0.37) 1.12 (0.27) 1.17 (0.42) 0.50
Systolic blood pressure (mmHg) 129.38 (12.08) 137.91 (12.96) 134.43 (13.41) 0.18
Duration of T2D (years)b 5.28 (3.75–9.00) 5.79 (2.50–11.00) 8.12 (5.00–12.00) 0.08
Age of T2D Onset (years) 56.79 (7.80) 54.09 (9.63) 53.74 (7.58) 0.21
Smoking  % (n) 4 % (n = 1) 22 % (n = 5) 22 % (n = 5) 0.11
Glycated haemoglobin (%)a 7.29 (4.92) 8.01 (8.70) 7.46 (9.98) 0.52
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However, it must be noted that the Cardiac Risk Pre-
diction array results for the SNPs LPA rs10455872 and 
APOA5 rs662799, which have similarly low MAFs, were 
in complete concordance with the other genotyping 
methods used. The SNP rs17456537, close to the gene 
MIA3 on chromosome 1, was the only SNP to have more 
than one discordant result between the Cardiac Risk Pre-
diction array and the pre-determined genotype for the 
blood-extracted DNA. While the molecular principles 
underlying the Cardiac Risk Prediction array have been 
used in other products, this is the first to use for genotyp-
ing. Given the high concordance between the array and 
other “gold-standard” methods such as TaqMan, we can 
be confident that the genotyping was accurate and thus 
the gene score calculated on the basis of this was a true 
reflection of the participant’s genetic CHD risk.
The distribution of risk alleles in the sample healthy UK 
men can be seen to be normally distributed. While in the 
CoRDia SMI + RR group the distribution does not show 
the same classic “bell-curve” and normally distributed 
characteristics, this can be attributed to the relatively 
low number of participants. As there was no significant 
difference in the mean gene score of the genotyped CoR-
Dia recruits and the large cohort of healthy UK men, we 
can conclude that the genetic CHD risk observed in our 
cohort is typical of the UK population, and therefore, we 
believe that the results of the study can be extrapolated to 
the general population, for example in the reaction of the 
participants to their genetic risk. While the CorDia sub-
jects would be expected to have inherited a greater than 
average number of T2D risk alleles, the similar mean 
score for CHD risk alleles between the diabetic group 
and the UK healthy subjects is in line with GWAS stud-
ies that show that the genetic architecture of CHD and 
T2D are different, demonstrating by the fact that few of 
the CHD risk and T2D risk loci overlap [17, 18].
Both the SNPs included in the gene score and the 
weights of CHD risk associated with carriage of each risk 
allele [9] were obtained from studies with Caucasian par-
ticipants. While the results of such studies will not reflect 
the underlying genetic architecture of CHD across all 
ethnicities, this is by far the largest source of data. There-
fore and especially given that over 90 % of participants of 
the CoRDia study are Caucasian, the use of the 19 SNP 
gene score is appropriate for this cohort. Furthermore, 
while we accept that relatively small sample size is a limi-
tation of the study, the use of the combined weighted 
gene score as the single major genetic variable examined, 
overcomes the potential problem of low power resulting 
from the inclusion of rare variants within the 19 SNPs. 
While many more SNPs have now been identified to be 
associated with risk of CHD by GWAS and the meta-
analysis of these data [17], the 19 SNP CHD gene score 
used here has been previously found to be associated 
with CHD in subjects of both Caucasian [9] and Afro-
Caribbean ethnicity [10], although the relationship with 
CHD in those of South Asian ethnicity requires further 
clarification [9]. Addition of further SNPs may improve 
the utility of such SNP scores in the future [19, 20].
In large part, the gene score captures information not 
included as part of the assessment of CHD risk by the 
UKPDS score. In the healthy UK subjects the score was 
significantly associated with higher LDL-cholesterol, 
Fig. 2 Distribution of risk alleles in a UK healthy men (n = 1360) 
and b CoRDia participants of Caucasian ethnicity in the SMI plus risk 
results arm (n = 66)*
Fig. 3 Boxplot of gene score in UK healthy men and the CoRDia SMI 
plus risk results arm. The mean weighted gene score for each group 
is marked in red (horizontal line represents the median) and these 
were compared using a t test (p = 0.80). Non-Caucasian participants 
were removed from the CoRDia SMI plus risk results profile group. The 
number of participants in each was as follows, NPHSII n = 1360 and 
CoRDia plus risk results n = 66
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which reflects the inclusion of SNPs in several genes 
involved in LDL-cholesterol metabolism (APOB, PCSK9, 
APOE, CETP) and, not surprisingly for a genetic instru-
ment, with higher family history of CHD, which has 
previously been shown to be an independent risk factor 
for CHD in this cohort [12] and many others [21, 22]. 
However, the score was not significantly associated with 
other CHD or T2D-specific risk factors (total choles-
terol, HDL-cholesterol, age, smoking, systolic blood pres-
sures, BMI and risk of diabetes). In the smaller CoRDia 
SMI  +  RR cohort, the gene score was not significantly 
associated with any of the CHD-risk variables included in 
the UKPDS score, indicating that the gene score is cap-
turing information concerning CHD risk over and above 
that captured by the UKPDS score. Therefore, inclusion 
of the gene score in risk prediction may improve the 
performance of the UKPDS risk tool alone. Since the 
composition of the gene score was finalised dozens of 
robustly association CHD risk loci have been identified 
primarily by the CARDIoGRAM consortium [23]. Inclu-
sion of these variants in the gene score may improve its 
performance and provide a more accurate measure of an 
individual’s genetic risk of CHD, although the use of such 
gene score has given mixed results [19, 20].
In summary, baseline 10-year CHD risk did not dif-
fer significantly between the randomisation groups. We 
found the Randox Cardiac Risk Prediction Array results to 
be over 99.8 % concordant with other genotyping meth-
ods and used it to successfully genotype the SMI +  RR 
arm of the CoRDia study. The gene score was modestly 
associated with effects on two well-known CHD risk fac-
tors, namely LDL-cholesterol and family history of CHD, 
but as was expected, there was no evidence of a higher 
gene score in the diabetic subjects compared to healthy 
UK subjects, confirming the lack of bias in recruitment.
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